JosephLLaskyIIIMD

Pediatric Hematology & Oncology • Las Vegas, NV

Medical Director, Pediatric Hematology/Oncology, Cure 4 The Kids Foundation

Join to view full profile

Dr. Lasky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lasky's full profile

Already have an account?

Office
1 Breakthrough Way
Las Vegas, NV 89135
Phone+1 702-732-1493

Fax+1 702-732-1080

Summary

Dr. Joseph Lasky is a pediatric hematologist/oncologist in Las Vegas, NV. He received his medical degree from University of Illinois College of Medicine and has been in practice 17 years. He is experienced in sickle-cell anemia, pediatric sarcomas, leukemia, pediatric bone marrow transplantation, and pediatric hematopoietic stem cell transplantation.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 2003 - 2006
University of ChicagoResidency, Pediatrics, 2000 - 2003
University of Illinois College of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2003 - 2026
NV State Medical License 2017 - 2025
IL State Medical License 2000 - 2003
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma Start of enrollment: 2005 Jan 01
Completed
Phase 1
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A Start of enrollment: 2013 Mar 01
Unknown status
Phase 3
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections Start of enrollment: 2017 May 11
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

121 citations
Notch signaling, brain development, and human disease
Joseph L. Lasky, Hong Wu
Pediatric Research. 2005-05-01
58 citations
Cancer stem cells.
Wei Guo, Joseph L. Lasky, Hong Wu
Pediatric Research. 2006-04-01
155 citations
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Yutaka Niihara, Scott T Miller, Julie Kanter, Sophie Lanzkron, Wally R Smith
The New England Journal of Medicine. 2018-07-19

Journal Articles

A Phase 3 Trial of L-glutamine in Sickle Cell Disease
Rita Bellevue, Joseph L Lasky, Elliott P Vichinsky, Lewis L Hsu, Sharada Sarnaik, Lynne D Neumayr, Yutaka Niihara, Sophie Lanzkron, Ifeyinwa Osunkwo, Lance Sieger, Edu..., The New England Journal of Medicine

Abstracts/Posters

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial
Joseph Lasky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Consistent Benefit of L-Glutamine Observed across Patients with Low, Medium, and High Number of Crises Reported in the Year Prior to Screening -- Analysis from the Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Introducing Vegas Inc’s 2021 Top DoctorsAugust 26th, 2021